Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Windtree TherapeuticsWINT +100.00% Earnings per Share (Diluted) is $-8.51 as of Sep. 2025. The stock has 2 warning signs investors should review. Among 1,166 Biotechnology companies, Windtree Therapeutics ranks better than 95.97% on this metric.
During the past 3 years, the average EPS without NRIGrowth Rate was 82.70% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 63.80% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 63.00% per year.
During the past 13 years, Windtree Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 82.70% per year. The lowest was -4.50% per year. And the median was 55.85% per year.
Windtree Therapeutics (OTCPK:WINT) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Windtree Therapeutics Earnings per Share (Diluted) Related Terms
Windtree Therapeutics Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Windtree Therapeutics's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Windtree Therapeutics Earnings per Share (Diluted) Chart
WINT vs VRTX, REGN, RVMD: Earnings per Share (Diluted) Comparison
For the Biotechnology subindustry, Windtree Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Windtree Therapeutics PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Windtree Therapeutics's PE Ratio distribution charts can be found below:
* The bar in red indicates where Windtree Therapeutics's PE Ratio falls into.
Windtree Therapeutics Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Windtree Therapeutics's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2024 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.51
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $-8.51 mean?
Windtree Therapeutics (WINT) has a Earnings per Share (Diluted) of $-8.51 as of Sep. 2025. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Windtree Therapeutics and its competitors. According to the industry distribution chart, Windtree Therapeutics ranks #47 out of 1166 companies in the Biotechnology industry, placing it in the top 4%.
Is Windtree Therapeutics' Earnings per Share (Diluted) too high?
Windtree Therapeutics' current Earnings per Share (Diluted) is $-8.51. Based on the distribution chart, Windtree Therapeutics ranks #47 out of 1166 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Windtree Therapeutics' Earnings per Share (Diluted) compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Windtree Therapeutics ranks #47 out of 1166 companies for Earnings per Share (Diluted). This places Windtree Therapeutics in the top 4% of its industry — outperforming the majority of peers. The industry median Earnings per Share (Diluted) is 16.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Biotechnology company?
The median Earnings per Share (Diluted) among Biotechnology companies is 16.20, based on 1,166 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Windtree Therapeutics and its competitors. For the Biotechnology industry, the median Earnings per Share (Diluted) is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Windtree Therapeutics's current Earnings per Share (Diluted) is $-8.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windtree Therapeutics stock overvalued right now?
Windtree Therapeutics (WINT) has a current Earnings per Share (Diluted) of $-8.51. The current Earnings per Share (Diluted) is $-8.51. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Windtree Therapeutics (WINT), the current Earnings per Share (Diluted) is $-8.51 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WINT has been successfully added to your 
